dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Ch, F. Tolis | en |
dc.contributor.author | Kalogera-Fountzila, Anna | en |
dc.contributor.author | Misailidou, D. | en |
dc.contributor.author | Tsekeris, P. | en |
dc.contributor.author | Karina, M. | en |
dc.contributor.author | Nikolaou, A. | en |
dc.contributor.author | Samantas, E. | en |
dc.contributor.author | Makatsoris, T. | en |
dc.contributor.author | Athanassiou, E. | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Bamias, A. T. | en |
dc.contributor.author | Zamboglou, N. | en |
dc.contributor.author | Economopoulos, T. | en |
dc.contributor.author | Karanastassi, S. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Daniilidis, J. | en |
dc.creator | Fountzilas, George | en |
dc.creator | Ch, F. Tolis | en |
dc.creator | Kalogera-Fountzila, Anna | en |
dc.creator | Misailidou, D. | en |
dc.creator | Tsekeris, P. | en |
dc.creator | Karina, M. | en |
dc.creator | Nikolaou, A. | en |
dc.creator | Samantas, E. | en |
dc.creator | Makatsoris, T. | en |
dc.creator | Athanassiou, E. | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Bamias, A. T. | en |
dc.creator | Zamboglou, N. | en |
dc.creator | Economopoulos, T. | en |
dc.creator | Karanastassi, S. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Daniilidis, J. | en |
dc.date.accessioned | 2018-06-22T09:53:08Z | |
dc.date.available | 2018-06-22T09:53:08Z | |
dc.date.issued | 2005 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41679 | |
dc.description.abstract | The primary objective of this phase II study was to access the complete response (CR) rate to a new innovative induction regimen in patients with locally advanced head and neck cancer (LA-HNC). From October 2000 until October 2003 a total of 38 eligible patients (33 men and 5 women) entered the study. The large majority of them presented with a performance status of 0-1 and with clinical stage IV disease. Treatment consisted of three cycles of induction chemotherapy (IC) with paclitaxel 175 mg/m2 in a 3-h infusion on d 1, leucovorin (LV) 200 mg/m2 over 20 min immediately followed by FU 400 mg/m2 bolus and then 600 mg/m2 as a 24-h continuous infusion on d 1 and 2 and a cisplatin 75 mg/m2 over 1-h infusion on d 2 every 3 wk. This was then followed by radiation (70 Gy) and weekly cisplatin 40 mg/m2. After the completion of IC, 6/38 (16%) patients had CR. The CR rate was increased to 66% post-concomitant chemoradiotherapy (CCRT). Neutropenia (37.5%), pain (62%), nausea/vomiting (21%), and alopecia (79%) were the most frequent side effects during IC. The most pronounced toxicities during chemoradiotherapy were stomatitis (62.5%) and xerostomia (53%). Median time to progression was 11.0 mo and median survival 16.7 mo. One- and 2-yr survival rates were 73% and 38%, respectively. In conclusion, this novel induction regimen is active, is well tolerated, and can be successfully followed by CCRT with weekly cisplatin. CCRT should remain standard treatment for patients with LA-HNC. Novel induction combinations, such as that reported in the present study, should be evaluated in combination with CCRT only in the context of clinical trials. © Copyright 2005 by Humana Press Inc. All rights of any nature whatsoever reserved. | en |
dc.language.iso | eng | en |
dc.source | Medical Oncology | en |
dc.subject | Article | en |
dc.subject | Cisplatin | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer growth | en |
dc.subject | Cancer survival | en |
dc.subject | Chemotherapy | en |
dc.subject | Follow up | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Anorexia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Constipation | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Fatigue | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Infection | en |
dc.subject | Leukopenia | en |
dc.subject | Mucosa inflammation | en |
dc.subject | Myalgia | en |
dc.subject | Nausea and vomiting | en |
dc.subject | Neurotoxicity | en |
dc.subject | Neutropenia | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Recombinant granulocyte colony stimulating factor | en |
dc.subject | Stomatitis | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Treatment outcome | en |
dc.subject | Infusions | en |
dc.subject | Intravenous | en |
dc.subject | Cancer staging | en |
dc.subject | Drug dose regimen | en |
dc.subject | Pain | en |
dc.subject | Folinic acid | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Injections | en |
dc.subject | Side effect | en |
dc.subject | Leucovorin | en |
dc.subject | Bolus injection | en |
dc.subject | Continuous infusion | en |
dc.subject | Dysphagia | en |
dc.subject | Weight reduction | en |
dc.subject | Xerostomia | en |
dc.subject | Squamous cell | en |
dc.subject | Squamous cell carcinoma | en |
dc.subject | Peripheral neuropathy | en |
dc.subject | Paclitaxel | en |
dc.subject | Combined modality therapy | en |
dc.subject | Hypersensitivity reaction | en |
dc.subject | Head and neck neoplasms | en |
dc.subject | Head and neck cancer | en |
dc.subject | Laboratory test | en |
dc.subject | Head and neck carcinoma | en |
dc.subject | Dermatitis | en |
dc.subject | Hoarseness | en |
dc.subject | Otitis | en |
dc.subject | Patient selection | en |
dc.subject | Taste disorder | en |
dc.subject | Treatment withdrawal | en |
dc.title | Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: A hellenic cooperative oncology group phase II study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1385/MO:22:3:269 | |
dc.description.volume | 22 | |
dc.description.issue | 3 | |
dc.description.startingpage | 269 | |
dc.description.endingpage | 279 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Kalogera-Fountzila, Anna [0000-0002-6801-3129] | |
dc.gnosis.orcid | 0000-0002-2195-9961|0000-0002-6801-3129 | |